@article {Albin2020.10.11.20210914, author = {Roger L. Albin and Martijn L.T.M. M{\"u}ller and Nicolaas I. Bohnen and Cathie Spino and Martin Sarter and Robert A. Koeppe and Ashley Szpara and Cindy Lustig and William T. Dauer}, title = {α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease}, elocation-id = {2020.10.11.20210914}, year = {2020}, doi = {10.1101/2020.10.11.20210914}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objective Attentional function deficits secondary to degeneration of brain cholinergic systems are significant contributors to gait-balance deficits in Parkinson disease (PD). To assess whether α4β2* nicotinic acetylcholine receptor (nAChR) stimulation improves attention and gait-balance function, we performed a target engagement study of the α4β2* nAChR partial agonist varenicline.Methods Non-demented PD participants with cholinergic deficits were identified with [18F]fluoroethoxybenzamicol positron emission tomography (PET). α4β2* nAChR occupancy after subacute oral varenicline treatment was measured with [18F]flubatine PET. With a dose selected from the receptor occupancy experiment, varenicline effects on gait, balance, and cognition were assessed in a double-masked placebo-controlled crossover study. Primary endpoints were normal pace gait speed and a measure of postural stability.Results Varenicline, 0.25 mg per day, 0.25 mg b.i.d., 0.5 mg b.i.d., and 1.0 mg b.i.d., produced 60\% - 70\% receptor occupancy, with 0.5 mg po b.i.d chosen for the crossover study. Thirty-three (of thirty-four) participants, completed the crossover study with excellent tolerability. Varenicline had no impact on the postural stability measure and resulted in slower normal pace gait speed. Varenicline reduced distraction effects under dual task gait conditions and improved performance on a sustained attention test. In 28 participants in whom treatment compliance was confirmed by plasma varenicline measurements, we obtained identical conclusions.Interpretation Varenicline occupied a significant fraction of α4β2* nicotinic acetylcholine receptors, was tolerated well, enhanced attentional function, and improved dual task gait performance. α4β2* nicotinic agonists may be useful in mitigating gait and balance disorders in PD.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04403399; NCT02933372Funding StatementSupported by: NIH-NINDS, Michael J. Fox Foundation, and the Parkinson{\textquoteright}s FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Michigan IRBMED.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on request.}, URL = {https://www.medrxiv.org/content/early/2020/10/14/2020.10.11.20210914}, eprint = {https://www.medrxiv.org/content/early/2020/10/14/2020.10.11.20210914.full.pdf}, journal = {medRxiv} }